6 stories mentioning CGNX
Every FINWIRES story that references CGNX, newest first.
Cognex (CGNX) shares were up 2.5% in Tuesday trading after JPMorgan upgraded the company's stock to overweight from neutral and adjusted its price target to $75 from $65.Trading volume stood at about 1.1 million shares, compared with a daily average of about 2.2 million.Price: $67.85, Change: $+1.76, Percent Change: +2.66%
Cognex (CGNX) has an average rating of overweight and mean price target of $75.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Laura Ann Macdonald, Vice President and Principal Accounting Officer, on May 11, 2026, sold 139,722 shares in Cognex (CGNX) for $9,282,195. Following the Form 4 filing with the SEC, Macdonald has control over a total of 5,278 common shares of the company, with 5,258 shares held directly and 20 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/851205/000177370426000018/xslF345X05/edgardoc.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $76 from $66, on a forward P/E of 46x our 2027 EPS projection of $1.65. We raise our 2026 EPS view to $1.39 from $1.16 and adjust our 2027 forecast to $1.65 from $1.47. Q1 2025 revenue rose 24% Y/Y to $268M, ahead of expectations, driven by broad-based strength across end markets and geographies. On the profitability front, adjusted gross margin expanded 420 bps to 71.8% and adjusted EBITDA margin of 26.9% exceeded guidance by over 600 bps, reflecting cost discipline and execution. Management remains focused on efficiency initiatives, making further progress toward achieving its $35M to $40M annualized net cost savings target by the end of the year, and we see a path to sustained double-digit EPS growth in the near term. Innovations (In-Sight 6900 and In-Sight 3900) announced during the quarter, positioning CGNX as a leading provider of AI-powered machine vision technologies.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CGNX delivered solid Q1 2026 results with revenue of $268M (+24% Y/Y), beating consensus by $22M, while adjusted EPS of $0.34 (+113% Y/Y) exceeded expectations by $0.09. Margin expansion continued with adjusted EBITDA margin reaching 26.9% (+1,010 bps Y/Y) and operating margin surging to 22.3% (+1,020 bps), demonstrating exceptional operational leverage. We believe this validates the diversification strategy and suggests industrial automation recovery is gaining momentum. Strong cash generation produced $42.3M in free cash flow (+11% Y/Y), while the company returned $113M to shareholders and maintains $622M in cash with zero debt. Q2 guidance indicates continued momentum with revenue expected at $280M-$300M and adjusted EPS of $0.40-$0.44 (+68% Y/Y at midpoint), above consensus of $0.30. We see the combination of technology leadership, operational excellence, and end-market diversification positioning CGNX well for sustained outperformance through the automation cycle.
Cognex (CGNX) said Tuesday it has launched the In-Sight 6900 Vision Controller, a system designed to improve industrial inspection.Unlike fixed systems, this modular controller lets manufacturers configure cameras, optics, and lighting to match their specific inspection needs, and is powered by NVIDIA (NVDA) Jetson technology, which allows it to deliver high-capacity artificial intelligence processing at the edge without needing external computers or complex architectures, the company said.The system also works with Cognex's OneVision platform, which allows teams to build, improve, and scale inspection programs across multiple locations, the company added.Shares of Cognex fell 3.4% and NVIDIA was down 3% in the session.Price: $53.23, Change: $-1.86, Percent Change: -3.37%